An overview of the optimal planning, design, and conduct of phase i studies of new therapeutics

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1710-1718

  LoRusso, Patricia M ^a   Boerner, Scott A ^a   Seymour, Lesley ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; BIOLOGICAL MARKER; GDC 0449; PHOSPHOTRANSFERASE INHIBITOR; PLX 4032; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CLINICAL TRIAL; CONSENSUS; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PHASE 1 CLINICAL TRIAL; PLANNING; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77949669232     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1993     Document Type: Review

References (44)

1. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in Development for Cancer. http://www.phrma.org. 1987-2009; Available from: http://www.phrma.org.
2. U.S. Department of Health and Human Services Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. US Department of Health and Human Services; 2004. Available from: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
4. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007;6:1175-9.
5. Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev 1998;18:299-314.
6. Senderowicz A. Information needed to conduct first-in-human oncology trials in the U.S. A view from a former FDA medical reviewer. Clin Cancer Res 2010;16:1719-25.
7. Hirschfeld S, Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002;42:137-43.
8. Viale PH, Moore S. Postmarketing surveillance for oncology drugs. Clin J Oncol Nurs 2008;12:877-86.
9. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8.
10. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003; 2:131-8.
11. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986;70:73-80.
12. Ivy SP, Siu L, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency and selected patient populations: A report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 2010;16:1726-36.
13. Heath EI, LoRusso PM, Ivy SP, Rubinstein L, Christian MC, Heilbrun LK. Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience. J Biopharm Stat 2009;19:414-23.
14. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004;96:990-7.
15. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
16. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol 2007;25:4982-6.
17. Forster MD, Saijo N, Seymour L, Calvert AH. Performing phase I clinical trials of anticancer agents: perspectives from within the European Union and Japan. Clin Cancer Res 2010;16:1737-44.
18. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 2005;24:2171-81.
19. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst 2004;96:977-8.
20. Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med 2006;25:2365-83.
21. LoRusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs 2008;17:1013-28.
22. LoRusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006;24:Abstract 3034.
23. Mita AC, Wang D, Takimoto CH, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. J Clin Oncol 2007; 25:14033.
24. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-8.
25. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 1998;9:1047-52.
26. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-55.
27. Comets E, Zohar S. A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. Clin Pharmacokinet 2009;48:387-95.
28. McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009;27:5650-9.
29. Ely S. Personalized medicine: individualized care of cancer patients. Transl Res 2009;154:303-8.
30. Widakowich C, de Azambuja E, Gil T, et al. Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol 2007;39:1375-87.
31. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-86.
32. Chapman P, Puzanov I, Sosman J, et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer Suppl 2009;7:5.
33. Janku F, Garrido-Laguna I, Hong DS. PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. 2009 AACRNCI-EORTC Molecular Targets and Cancer Therapeutics Conference. 2009, p. Abstract B134.
34. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-72.
35. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. Eur J Cancer Suppl 2009;7:8.
36. LoRusso PM. Phase 0 clinical trials: an answer to drug development stagnation? J Clin Oncol 2009;27:2586-8.
37. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007;7:325-34.
38. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry. Investigators, and Reviewers - Exploratory IND Studies. 2006. Available from: http://www.fda.gov/cder/guidance/7086fnl.htm.
39. Doroshow JH, Parchment RE. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res 2008;14:3658-63.
40. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
41. Sun H, Collins JM, Mangner TJ, Muzik O, Shields AF. Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies. Cancer Chemother Pharmacol 2006;57:343-8.
42. Takimoto CH. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Eur J Cancer 2009;45:436-8.
43. Rock EP, Molloy VJ, Humphrey JS. Data quality for academic investigators. Clin Cancer Res 2010;16:1756-63.
44. Seymour S, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L. The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 2010;16:1764-9.